Notice of General Meeting 2019

March 13, 2019 Kerry Rowe

Post navigation

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Notice of General Meeting 2019

Related Posts

Prana Completes Phase 2 Huntington Disease Trial with PBT2

Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MA

Parkinson’s UK Awards £150,000 to Study Prana’s PBT434